Data as of 10:18am ET
| -0.38 / -4.51%|
Sangamo BioSciences, Inc. is a clinical stage biopharmaceutical company, which is focused on the research, development, and commercialization of engineered DNA-binding proteins in the creation of novel therapeutic strategies for unmet medical needs. The company's technologies include the development of human therapeutics, plant agriculture, and the enhancement of pharmaceutical protein production. ZFP Therapeutic is the company's registered trademark. It has a Phase 2 and two Phase 1/2 clinical trials to evaluate the safety and the clinical effect of a treatment for HIV/AIDS. Additionally, Sangamo BioSciences has another Phase 1 trial to evaluate the safety and the clinical effect of a treatment for recurrent glioblastoma multiforme. The company's product pipeline consists of SB-728, SB-509, and SB-313. Sangamo BioSciences was founded by Lanphier O. Edward II on June 22, 1995 and is headquartered in Richmond, CA.
|Edward O. Lanphier, II||President, Chief Executive Officer & Director|
|Henry Ward Wolff, MBA, CPA||Chief Financial Officer & Executive Vice President|
|Dale G. Ando, MD||Chief Medical Officer & VP-Therapeutic Development|
|Philip D. Gregory, PhD||Chief Scientific Officer & Vice President-Research|
|Geoffrey M. Nichol, MD, MBA||Executive Vice President-Research & Development|